AXIM Biotechnologies was granted a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application Serial Number 14/982,610. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from AXIM’s patent application, 14/982,610, filed in December 2015.
AXIM Biotech announced on March 21, 2017 that it retained the services of Ora, a global Contract Research Organization, to perform the company’s product development (based on AXIM’s IP) in glaucoma and dry eye syndrome utilizing cannabinoid-based therapeutics through its AX-1603 and AX-1606 clinical programs.
“As we move forward in our product development and clinical trials for glaucoma and dry eye, this patent approval by the USPTO is paramount for us to be successful in finding new and improved cannabinoid-based treatment options for these highly-prevalent ophthalmic diseases with significant unmet medical needs,” George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, said in a company news release. “In 2016, global spending on glaucoma management was $6 billion, so we are excited about the opportunity that this new patent grants us to develop new treatments with novel mechanisms of action that will in turn reduce the risk of progression of visual field loss.”